| Dr John David Welander, MD | |
|
405 Monroe St, Pella, IA 50219-1189 | |
| (641) 628-6772 | |
| (641) 621-2326 |
| Full Name | Dr John David Welander |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 15 Years |
| Location | 405 Monroe St, Pella, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245466515 | NPI | - | NPPES |
| 41662 | Other | IA | IOWA LICENSE |
| 1245466515 | Other | NPI NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 41662 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pella Regional Health Center | Pella, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pella Regional Health Center | 9931005873 | 82 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Scientists have discovered an important enzyme molecule that may prevent fatal cardiac disorders associated with cardiac hypertrophy - the leading cause of sudden cardiac death in young athletes.
Years of research in University of Illinois scientist John Erdman's laboratory have demonstrated that lycopene, the bioactive red pigment found in tomatoes, reduces growth of prostate tumors in a variety of animal models. Until now, though, he did not have a way to trace lycopene's metabolism in the human body.
The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.
› Verified 8 days ago
| Entity Name | Pella Regional Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053369405 PECOS PAC ID: 9931005873 Enrollment ID: O20031210000914 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Scientists have discovered an important enzyme molecule that may prevent fatal cardiac disorders associated with cardiac hypertrophy - the leading cause of sudden cardiac death in young athletes.
Years of research in University of Illinois scientist John Erdman's laboratory have demonstrated that lycopene, the bioactive red pigment found in tomatoes, reduces growth of prostate tumors in a variety of animal models. Until now, though, he did not have a way to trace lycopene's metabolism in the human body.
The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John David Welander, MD 405 Monroe St, Pella, IA 50219-1189 Ph: (641) 628-6772 | Dr John David Welander, MD 405 Monroe St, Pella, IA 50219-1189 Ph: (641) 628-6772 |
News Archive
City of Hope researchers received approval from the U.S. Food and Drug Administration (FDA) to conduct the first-in-human study of a neural stem cell-based therapy targeting recurrent high-grade gliomas, the most aggressive type of brain tumor. Karen S. Aboody, M.D., associate professor in City of Hope's Department of Neurosciences, leads the research team that developed this treatment strategy. Jana Portnow, M.D., assistant professor and assistant director of the Brain Tumor Program at City of Hope, is the principal investigator for the clinical trial.
Scientists have discovered an important enzyme molecule that may prevent fatal cardiac disorders associated with cardiac hypertrophy - the leading cause of sudden cardiac death in young athletes.
Years of research in University of Illinois scientist John Erdman's laboratory have demonstrated that lycopene, the bioactive red pigment found in tomatoes, reduces growth of prostate tumors in a variety of animal models. Until now, though, he did not have a way to trace lycopene's metabolism in the human body.
The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.
› Verified 8 days ago
Dr. Matt Aaron Morgan, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 405 Monroe St, Pella, IA 50219 Phone: 641-628-6772 Fax: 641-621-2326 |